Darolutamide, also known as Nubeqa and made by Bayer, is recommended in final draft guidance to treat adults with metastatic hormone-sensitive prostate cancer in combination with androgen deprivation ...

HEMA was convened to be an independent voice guiding best practices in international health technology assessment (HTA). It aims to critically examine and assess new methods, and is a collaboration ...

The pipeline of potential treatments is encouraging. Several medicines are in development. Others including GLP-1 agonists like semaglutide (currently used for obesity treatment) are being repurposed ...

Adults with a first episode of psychosis start treatment in early intervention in psychosis services within 2 weeks of referral. Early intervention in psychosis services can improve clinical outcomes, ...

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...

Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays) Diagnostics ...

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...

Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults. This guidance updates ...

This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral ...

Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. This guidance updates and ...